Price Disclosure Reductions for 2025 October Cycle
The 2025 October cycle has a data collection period of 1 October 2024 to 31 March 2025.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 May 2025.
The reduction day is 1 October 2025.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Contents
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health, Disability and Ageing. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
These outcomes have been published in the National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025 published on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2025 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2025 will also take the reduction on 1 October 2025 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute was 11 July 2025.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.
Outcomes of Price Disclosure calculations
| Legal Instrument Drug | Legal Instrument Form | Legal Instrument MoA | Brands of PI designated brands under 99ADHC (Y/N) | Floor Price | Price reduction applied in previous cycles (Y/N) | Average Unadjusted Price Reduction (UPR) at least 12.5% over 3 consecutive cycles (Y/N) | June 2025 AEMP | October 2025 AEMP | Percentage difference between June 2025 and October 2025 AEMP (%) | UPR threshold (%) | Calculations based on: OWAPD = all brand data, or GWAPD = originator brand data removed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | Y | $40.30 | N | Y | $40.30 | $34.11 | 15.36% | 10% | GWAPD |
| Ambrisentan | Tablet 10 mg | Oral | N | - | - | - | $1,381.53 | $1,219.75 | 11.71% | 10% | GWAPD |
| Ambrisentan | Tablet 5 mg | Oral | N | - | - | - | $1,381.53 | $1,219.75 | 11.71% | 10% | GWAPD |
| Aprepitant | Capsule 165 mg | Oral | N | - | - | - | $55.17 | $49.52 | 10.24% | 10% | GWAPD |
| Atovaquone with proguanil | Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg | Oral | N | - | - | - | $51.22 | $46.03 | 10.13% | 10% | OWAPD |
| Bendamustine | Powder for injection containing bendamustine hydrochloride 100 mg | Injection | N | - | - | - | $124.07 | $58.49 | 52.86% | 10% | OWAPD |
| Bendamustine | Powder for injection containing bendamustine hydrochloride 25 mg | Injection | N | - | - | - | $31.02 | $14.62 | 52.87% | 10% | OWAPD |
| Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | Y | $5.15 | N | Y | $5.15 | $4.40 | 14.56% | 10% | GWAPD |
| Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | Y | $4.12 | N | Y | $4.12 | $4.00 | 14.56% | 10% | GWAPD |
| Bortezomib | Powder for injection 3.5 mg | Injection | N | - | - | - | $34.88 | $20.47 | 41.31% | 10% | OWAPD |
| Bortezomib | Solution for injection 3.5 mg in 1.4 mL | Injection | N | - | - | - | $34.88 | $20.47 | 41.31% | 10% | OWAPD |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Y | $169.30 | N | Y | $169.30 | $117.53 | 30.58% | 30% | OWAPD |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Y | $169.30 | N | Y | $169.30 | $117.53 | 30.58% | 30% | OWAPD |
| Cabergoline | Tablet 1 mg | Oral | N | - | - | - | $33.92 | $24.82 | 26.83% | 10% | OWAPD |
| Cabergoline | Tablet 2 mg | Oral | N | - | - | - | $45.46 | $33.27 | 26.81% | 10% | OWAPD |
| Cabergoline | Tablet 500 micrograms | Oral | N | - | - | - | $12.43 | $9.10 | 26.79% | 10% | OWAPD |
| Carbimazole | Tablet 5 mg | Oral | N | - | - | - | $9.62 | $6.25 | 35.03% | 10% | GWAPD |
| Dabigatran etexilate | Capsule 75 mg (as mesilate) | Oral | N | - | - | - | $10.33 | $8.50 | 17.72% | 10% | OWAPD |
| Dasatinib | Tablet 100 mg | Oral | N | - | - | - | $1,019.07 | $365.62 | 64.12% | 10% | GWAPD |
| Dasatinib | Tablet 20 mg | Oral | N | - | - | - | $618.71 | $221.98 | 64.12% | 10% | GWAPD |
| Dasatinib | Tablet 50 mg | Oral | N | - | - | - | $1,019.07 | $365.62 | 64.12% | 10% | GWAPD |
| Dasatinib | Tablet 70 mg | Oral | N | - | - | - | $1,261.67 | $452.66 | 64.12% | 10% | GWAPD |
| Dimethyl fumarate | Capsule (modified release) 240 mg | Oral | N | - | - | - | $392.81 | $300.62 | 23.47% | 10% | GWAPD |
| Donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral | Y | $5.46 | N | Y | $5.46 | $4.10 | 24.91% | 10% | GWAPD |
| Donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | Y | $5.46 | N | Y | $5.46 | $4.10 | 24.91% | 10% | GWAPD |
| Enalapril with hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | Oral | Y | $4.99 | N | Y | $4.99 | $4.21 | 15.63% | 10% | GWAPD |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Y | $34.14 | N | Y | $34.14 | $26.35 | 22.82% | 10% | OWAPD |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Y | $55.52 | N | Y | $55.52 | $42.86 | 22.80% | 10% | OWAPD |
| Ezetimibe | Tablet 10 mg | Oral | Y | $5.25 | N | Y | $5.25 | $4.35 | 17.14% | 10% | GWAPD |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | Y | $7.76 | N | Y | $7.76 | $6.20 | 20.10% | 10% | GWAPD |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | Y | $8.15 | N | Y | $8.15 | $6.51 | 20.12% | 10% | GWAPD |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | Y | $8.70 | N | Y | $8.70 | $6.95 | 20.11% | 10% | GWAPD |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | Y | $9.47 | N | Y | $9.47 | $7.56 | 20.17% | 10% | GWAPD |
| Fingolimod | Capsule 500 micrograms (as hydrochloride) | Oral | N | - | - | - | $829.79 | $695.70 | 16.16% | 10% | OWAPD |
| Flecainide | Tablet containing flecainide acetate 100 mg | Oral | N | - | - | - | $15.98 | $14.16 | 11.39% | 10% | GWAPD |
| Flecainide | Tablet containing flecainide acetate 50 mg | Oral | N | - | - | - | $12.89 | $11.42 | 11.40% | 10% | GWAPD |
| Flucloxacillin | Powder for injection 1 g (as sodium monohydrate) | Injection | Y | $8.50 | N | Y | $8.50 | $7.47 | 12.12% | 10% | OWAPD |
| Fluconazole | Capsule 100 mg | Oral | Y | $11.53 | N | Y | $11.53 | $9.55 | 17.17% | 10% | GWAPD |
| Fluconazole | Capsule 200 mg | Oral | Y | $22.47 | N | Y | $22.47 | $18.62 | 17.13% | 10% | GWAPD |
| Fluconazole | Capsule 50 mg | Oral | Y | $5.93 | N | Y | $5.93 | $4.91 | 17.20% | 10% | GWAPD |
| Fosaprepitant | Powder for I.V. infusion 150 mg | Injection | N | - | - | - | $69.23 | $58.22 | 15.90% | 10% | OWAPD |
| Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | N | - | - | - | $22.10 | $18.53 | 16.15% | 10% | GWAPD |
| Glipizide | Tablet 5 mg | Oral | N | - | - | - | $7.51 | $6.22 | 17.18% | 10% | OWAPD |
| Icatibant | Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe | Injection | N | - | - | - | $579.16 | $420.88 | 27.33% | 10% | OWAPD |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Y | $124.56 | N | Y | $124.56 | $80.03 | 35.75% | 30% | GWAPD |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Y | $249.11 | N | Y | $249.11 | $160.05 | 35.75% | 30% | GWAPD |
| Imatinib | Tablet 100 mg (as mesilate) | Oral | Y | $124.56 | N | Y | $124.56 | $80.03 | 35.75% | 30% | GWAPD |
| Imatinib | Tablet 400 mg (as mesilate) | Oral | Y | $249.11 | N | Y | $249.11 | $160.05 | 35.75% | 30% | GWAPD |
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | Oral | Y | $6.24 | N | Y | $6.24 | $5.07 | 18.75% | 10% | GWAPD |
| Isotretinoin | Capsule 10 mg | Oral | Y | $18.36 | N | Y | $18.36 | $15.89 | 13.45% | 10% | GWAPD |
| Isotretinoin | Capsule 20 mg | Oral | Y | $14.31 | N | Y | $14.31 | $12.39 | 13.42% | 10% | GWAPD |
| Lacosamide | Tablet 100 mg | Oral | N | - | - | - | $16.57 | $11.42 | 31.08% | 10% | GWAPD |
| Lacosamide | Tablet 150 mg | Oral | N | - | - | - | $24.85 | $17.12 | 31.11% | 10% | GWAPD |
| Lacosamide | Tablet 200 mg | Oral | N | - | - | - | $132.53 | $91.30 | 31.11% | 10% | GWAPD |
| Lacosamide | Tablet 50 mg | Oral | N | - | - | - | $8.28 | $5.70 | 31.16% | 10% | GWAPD |
| Lenalidomide | Capsule 10 mg | Oral | N | - | - | - | $548.44 | $400.72 | 26.93% | 10% | OWAPD |
| Lenalidomide | Capsule 15 mg | Oral | N | - | - | - | $660.53 | $482.63 | 26.93% | 10% | OWAPD |
| Lenalidomide | Capsule 20 mg | Oral | N | - | - | - | $844.46 | $505.16 | 40.18% | 10% | OWAPD |
| Lenalidomide | Capsule 25 mg | Oral | N | - | - | - | $864.20 | $631.44 | 26.93% | 10% | OWAPD |
| Lenalidomide | Capsule 5 mg | Oral | N | - | - | - | $418.64 | $305.88 | 26.93% | 10% | OWAPD |
| Letrozole | Tablet 2.5 mg | Oral | Y | $9.72 | N | Y | $9.72 | $7.55 | 22.33% | 10% | GWAPD |
| Levetiracetam | Tablet 250 mg | Oral | Y | $8.95 | N | Y | $8.95 | $7.18 | 19.78% | 10% | GWAPD |
| Levetiracetam | Tablet 500 mg | Oral | Y | $14.91 | N | Y | $14.91 | $11.96 | 19.79% | 10% | GWAPD |
| Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | Oral | Y | $25.48 | N | Y | $25.48 | $19.20 | 24.65% | 10% | GWAPD |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Y | $25.46 | N | Y | $25.46 | $19.18 | 24.67% | 10% | GWAPD |
| Pirfenidone | Tablet 267 mg | Oral | N | - | - | - | $150.26 | $123.41 | 17.87% | 10% | OWAPD |
| Pirfenidone | Tablet 801mg | Oral | N | - | - | - | $450.80 | $370.24 | 17.87% | 10% | OWAPD |
| Plerixafor | Injection 24 mg in 1.2 mL | Injection | N | - | - | - | $4,016.84 | $1,129.54 | 71.88% | 10% | GWAPD |
| Pomalidomide | Capsule 1 mg | Oral | N | - | - | - | $621.91 | $430.49 | 30.78% | 10% | OWAPD |
| Pomalidomide | Capsule 2 mg | Oral | N | - | - | - | $1,108.61 | $767.38 | 30.78% | 10% | OWAPD |
| Pomalidomide | Capsule 3 mg | Oral | N | - | - | - | $1,662.92 | $1,151.07 | 30.78% | 10% | OWAPD |
| Pomalidomide | Capsule 4 mg | Oral | N | - | - | - | $2,217.22 | $1,534.76 | 30.78% | 10% | OWAPD |
| Rasagiline | Tablet 1 mg (as mesilate) | Oral | N | - | - | - | $18.67 | $14.57 | 21.96% | 10% | GWAPD |
| Riluzole | Tablet 50 mg | Oral | Y | $113.30 | N | Y | $113.30 | $89.04 | 21.41% | 10% | GWAPD |
| Risperidone | Tablet 2 mg | Oral | Y | $8.90 | N | N | $8.90 | $6.22 | 30.11% | 30% | OWAPD |
| Risperidone | Tablet 3 mg | Oral | Y | $13.73 | N | N | $13.73 | $9.60 | 30.08% | 30% | OWAPD |
| Risperidone | Tablet 4 mg | Oral | Y | $18.52 | N | N | $18.52 | $12.95 | 30.08% | 30% | OWAPD |
| Rivaroxaban | Capsule 15 mg | Oral | N | - | - | - | $32.78 | $26.99 | 17.66% | 10% | OWAPD |
| Rivaroxaban | Capsule 20 mg | Oral | N | - | - | - | $32.38 | $26.66 | 17.67% | 10% | OWAPD |
| Rivaroxaban | Tablet 10 mg | Oral | N | - | - | - | $18.62 | $15.33 | 17.67% | 10% | OWAPD |
| Rivaroxaban | Tablet 15 mg | Oral | N | - | - | - | $32.78 | $26.99 | 17.66% | 10% | OWAPD |
| Rivaroxaban | Tablet 2.5 mg | Oral | N | - | - | - | $32.87 | $27.07 | 17.65% | 10% | OWAPD |
| Rivaroxaban | Tablet 20 mg | Oral | N | - | - | - | $32.38 | $26.66 | 17.67% | 10% | OWAPD |
| Tetrabenazine | Tablet 25 mg | Oral | N | - | - | - | $201.97 | $179.49 | 11.13% | 10% | GWAPD |
| Vinorelbine | Capsule 20 mg (as tartrate) | Oral | N | - | - | - | $46.05 | $38.18 | 17.09% | 10% | GWAPD |
| Vinorelbine | Capsule 30 mg (as tartrate) | Oral | N | - | - | - | $69.47 | $57.59 | 17.10% | 10% | GWAPD |
| Zoledronic acid | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | Injection | Y | $59.56 | N | Y | $59.56 | $45.72 | 23.24% | 10% | GWAPD |
Flow-on price disclosure reductions
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 October 2025 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-Oct-2025 (Excel 12KB).
Sponsors are able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
Indicative prices of brands scheduled for a price disclosure reduction
The indicative prices for brands scheduled for price disclosure reductions in this cycle were published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices reports have been replaced by the confirmed prices reports below.
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex‑manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2025 October cycle can be downloaded below.
Brand price reductions and savings to patients
The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 October 2025. This information is made available to assist patients understand how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report for the 2025 October cycle can be downloaded below.